Allogeneic marrow transplantation: the Seattle experience.
Allogeneic marrow transplantation from a normal donor provides potential life-saving therapy for a variety of inherited and acquired diseases of the hematopoietic system. Donor selection is a major issue, and most marrow transplants have been done only when an HLA-identical sibling donor has been available. Successful transplants can be done from partially HLA-matched relatives, but graft failure, graft rejection, and GvHD become increasingly serious complications as the number of HLA incompatibilities increase. More recently it has been shown that marrow transplants from HLA-identical unrelated donors can be successful. The recent development of a National Marrow Donor Program to recruit large numbers of HLA-typed volunteers and to facilitate the unrelated donor search process promises to make marrow transplants available to a growing number of patients.
Hansen
J A
JA
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Anasetti
C
C
Beatty
P G
PG
Martin
P J
PJ
Thomas
E D
ED
D016026:Bone Marrow Transplantation / Q000276:immunology*; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000517:prevention & control; D006680:HLA Antigens; D006801:Humans; D007165:Immunosuppression Therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000601:surgery; D015470:Leukemia, Myeloid, Acute / Q000601:surgery; D008212:Lymphocyte Depletion; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000601:surgery; D012042:Registries; D013601:T-Lymphocytes / Q000276:immunology; D014019:Tissue Donors; D014184:Transplantation, Homologous
D006680:HLA Antigens